ALTO-300 or placebo added to antidepressant treatment for major depression
About this title
Read the official source — NCT05922878Researchers are comparing ALTO-300 and placebo to find out how the approaches affect depression symptoms in adults with depression.
Understand this study
What is this study about?
Researchers are comparing ALTO-300 and placebo to find out how the approaches affect depression symptoms in adults with depression.
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.
What will I do during this study?
Depending on your group, you take an ALTO-300 or matching placebo (an inactive comparison treatment) capsule each evening from Day 1 to Day 42. The protocol also describes an open-label ALTO-300 period of up to eight weeks for participants admitted to that phase.
- Listed locations
- Phoenix and 74 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 325
- Sponsor
- Alto Neuroscience
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT05922878
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-300 With an Open-Label Extension in Adults With Major Depressive Disorder
Recruitment & locations
Phoenix · Yuma · Rogers
64 more locations
- Bellflower
- Carlsbad
- Glendale
- Lafayette
- Los Angeles
- Mather
- Mission Viejo
- Moorpark
- Temecula
- Colorado Springs
- Denver
- Evergreen
- Norwalk
- Clermont
- Miami Gardens
- Miami Lakes
- Okeechobee
- Tampa
- West Palm Beach
- Fayetteville
- Savannah
- Snellville
- Stone Mountain
- Blackfoot
- Boise
- Chicago
- Wichita
- Marrero
- Monroe
- Worcester
- Mankato
- Minneapolis
- Hattiesburg
- Jackson
- Creve Couer
- St Louis
- Omaha
- Las Vegas
- Albuquerque
- New York
- Rochester
- Staten Island
- Hickory
- Rose Hill
- Winston-Salem
- Cincinnati
- Oklahoma City
- Allentown
- Media
- Moosic
- Austin
- Conroe
- Dallas
- Fort Worth
- Houston
- Missouri City
- Plano
- Richmond
- San Marcos
- Stephenville
- Clinton
- Provo
- Fairfax
- Roanoke
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are comparing ALTO-300 and placebo to find out how the approaches affect depression symptoms in adults with depression.
Who is behind this study?
The study sponsor is Alto Neuroscience.
Does this study involve medication?
Yes. The study involves medication, including ALTO-300 and Placebo.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
